YEAR-END REPORT JANUARY-DECEMBER 2014

Summary: fourth quarter 2014

• Net sales improved marginally compared with the fourth quarter of 2013, SEK 2,099k (2,056k).

• Comprehensive income for the period was a loss of SEK 7,861k (loss: 5,313k).

• Earnings per share totaled SEK -0.36 (-0.34).

• Cash flow from operating activities was SEK -5,676k (-1,502k).

• Genovis established US subsidiary Genovis Inc.

• Genovis’ project for automatic analysis with the FabRICATOR enzyme showed proof-of-concept.

• Genovis filed a plaint against Promega Corporation for patent infringement since IdeS Protease is considered to infringe upon Genovis’ license for US patent No. 7.666.582.

Summary: full-year 2014

• Net sales fell by about 7 percent to SEK 8,252k (8,912k).

• Comprehensive income for the period was a loss of SEK 22,049k (loss: 15,853k).

• Earnings per share totaled SEK -1.02 (-1.10).

• Cash flow from operating activities was SEK -22,193k (-12,469k).

Challenging year brought us closer to our customers, while demonstrating the strength of our products.

After a tough start to the fall, we are pleased to note that fourth quarter sales rose 28 percent compared with the third quarter. Sales also increased slightly compared with Q4 2013. Sales fell mainly on the US market during the third quarter, but even here, sales are recovering. The number of new customers continues to grow as a result of the strategic shift from distribution through a number of partners to direct sales, though more importantly, because our products are reaching more customers. Genovis is now marketing its products directly in Europe and through an American wholly owned subsidiary in the US. In other parts of the world Genovis sells directly and via Sigma-Aldrich.

Over the course of the year our costs rose 11 percent. The costs are mainly related to the restructuring of sales channels, intensified sales activities and expenses related to the lawsuit against Promega. However, Genovis has an insurance policy to ensure that we minimize our legal costs in this case. Overall, with declining revenue especially during the third quarter, earnings for the period on an annualized basis fell short of our objective, mainly because of competition under circumstances that could not be predicted. New situations can arise at any time and our philosophy is to be proactive by increasing interaction and cooperation with our customers, intensifying our marketing initiatives, and continuing to focus on our strategic product pipeline. In this way, we will reverse the trend of this past autumn to achieve growth in 2015.

Genovis’ product FabRICATOR® has initiated a paradigm shift for the methods that the pharmaceutical industry uses to characterize and analyze biological medicines. This new technology is now accepted and on the path to becoming more broadly established. Our strategy is to ensure that we are first with the next generation of products that support and develop this method of analysis. Our customers have strong confidence in us as a result of FabRICATOR. We will take advantage of synergies based on this confidence by growing with more products which, like FabRICATOR, will give the customer results at a lower cost and with high reliability. Consequently we are prioritizing products in Genovis’ pipeline that can be used for several different proteins, and not just antibody-based drugs. These easy-to-use products enable the customer to carry out several different analyses in addition to those already made possible by FabRICATOR. Because of new discoveries in the fourth quarter, we wanted to explore potential IP issues before a launch, but in 2015 we will launch at least three new products.

Genovis is also prioritizing products intended for automation and miniaturization of characterization of biological medicines. The MAbCheck project, in which Genovis is developing automated analysis solutions together with researchers from Lund Institute of Technology, has reached the proof-of-concept stage, which will now be verified by a number of major industrial players. The results will be presented during the spring of 2015.

Our subsidiary GeccoDots concluded the VINNOVA-financed project aimed at developing a new contrast agent for ultrasound with very good results during the fourth quarter. The next step in the project is to complete the prototype and conduct toxicity and proof-of- concept studies for diagnosis of lymph nodes in an animal model.

All in all, 2014 posed certain challenges, but the year also brought positive developments, especially regarding sales of the products launched in 2013. This trend appears to be continuing. Our work with new products is promising for product launches this year and for Genovis’ growth in new markets in the long term.

Sarah Fredriksson

CEO, Genovis AB

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is Certified Adviser for the Company, t: +46 (0)31-745 50 00